The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: Design and methods

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Kardos, Peter ^a   Vogelmeier, Claus ^b   Buhl, Roland ^c   Criée, Carl Peter ^d   Worth, Heinrich ^e  

^a Group Practice and Allergy   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d Evangelical Hospital Goettingen Weende   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

COPD; Non interventional study; Out patient; Pharmacological therapy; Register

Indexed keywords

GLYCOPYRRONIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLYCOPYRRONIUM;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE MANAGEMENT PROGRAM; DRUG SAFETY; FOLLOW UP; GERMANY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; LUNG FUNCTION; MEDICATION COMPLIANCE; METHODOLOGY; OUTPATIENT CARE; PATIENT ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SECONDARY HEALTH CARE; STUDY DESIGN; TREATMENT OUTCOME; ADULT; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; MULTICENTER STUDY; OUTPATIENT; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; BRONCHODILATOR AGENTS; FEMALE; FOLLOW-UP STUDIES; GERMANY; GLYCOPYRROLATE; HUMANS; MALE; OUTPATIENTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; TREATMENT OUTCOME;

EID: 84928733625     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-15-2     Document Type: Article

References (28)

1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al.: International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. 10.1016/S0140-6736(07)61377-4
2. Pritzkuleit R, Beske F, Katalinic A: Erkrankungszahlen in der Pneumologie - eine Projektion bis 2060. Pneumologie 2010, 64:535-540. 10.1055/s-0030-1255637
3. Orie NG, Sluiter HJ, de Vries K, Tammeling GJ, Witkop J: The host factor in Bronchitis. In Bronchitis. Edited by: Orie NG, Sluiter HJ. The Netherlands: Royal Van Gorcum Assen; 1961:43-59.
4. Filley GF, Dart GA, Mitchell RS: Emphysema and chronic bronchitis: clinical manifestations and their physiological significance. Aspen Emphysema Conf. Aspen, Co. USA 1968, 9:339-349. PMID 5722666
5. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute; 2001:1-100. NIH Publication No 2701
6. Fletcher C, Peto R, Tinker CM: The Natural History of Chronic Bronchitis and Emphysema. Oxford: Oxford University Press; 1976.
7. Tashkin DP: Variations in FEV(1) decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med 2013, 19:116-124. 10.1097/MCP.0b013e32835d8ea4
8. Akkermans RP, Berrevoets MA, Smeele IJ, Lucas AE, Thoonen BP, Grootens-Stekelenburg JG, et al.: Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects. BMC Pulm Med 2012, 12:12. 10.1186/1471-2466-12-12
9. Mohamed Hoesein FA, Zanen P, Boezen HM, Groen HJ, van Ginneken B, de Jong PA, et al.: Lung function decline in male heavy smokers relates to baseline airflow obstruction severity. Chest 2012, 142:1530-1538. 10.1378/chest.11-2837
10. ZuWallack RL, Nici L: Modifying the course of chronic obstructive pulmonary disease: looking beyond the FEV1. COPD 2012, 9:637-648. 10.3109/15412555.2012.710668
11. Rabe K, Wedzicha JA, Wouters E: COPD and Comorbidity. Edited by: European Respiratory Monograph. Sheffield: European Respiratory Society; 2013:1-228. ISBN ISBN 978-1-84984-032-3
12. Han MK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA, Jones PW, Anzueto A, Martinez FJ, Crapo JD, Silverman EK, Make BJ: GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013,1(1):43-50. 10.1016/S2213-2600(12)70044-9
13. Wedzicha JA: GOLD and ABCD? A good start, but now for the evidence? Lancet Respir Med 2013,1(1):4-5. 10.1016/S2213-2600(12)70045-0
14. Hausen T: New GOLD Guidelines for Treatment of COPD [Neue GOLD-Leitlinie zur Therapie der COPD]. Pneumologie 2012, 66:768.
15. Jones R, Price D, Chavannes N, van de Molen T, Thomas M, Tsiligianni I, Williams S: GOLD COPD categories are not fit for purpose in primary care. Lancet Respir Med 2013,1(1):e17.
16. Han MK, Lange P, Anzueto A, Martinez FJ, Jones PW: GOLD COPD categories are not fit for purpose in primary care? Authors' reply. Lancet Respir Med 2013,1(1):e17-e18.
17. Pisa G, Freytag S, Schandry R: Chronic Obstructive Pulmonary Disease (COPD) patients' disease-related preferences: a study using conjoint analysis. Patient 2013, 6:93-101. 10.1007/s40271-013-0007-2
18. Cochrane A: Effectiveness and Efficiency: Random Reflection on Health Services. London: Nuffield Provincial Hospital Trusts; 1972.
19. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al.: Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008, 31:869-873. 10.1183/09031936.00111707
20. Witt C, Tresz A, Wegscheider K: Externer Validität auf der Spur. Dtsch Arztebl 2011,108(46):2468-2474.
21. Corrado A, Rossi A: How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012, 106:989-997. 10.1016/j.rmed.2012.03.008
22. Bourbeau J, Tan WC, Benedetti A, Aaron SD, Chapman KR, Coxson HO, et al.: Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD. COPD 2014, 11:125-32. 10.3109/15412555.2012.665520
23. Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M, et al.: External validity of randomized controlled trials in COPD. Respir Med 2007, 101:1313-1320. 10.1016/j.rmed.2006.10.011
24. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al.: Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161. 10.1164/rccm.201201-0034OC
25. Beasley R, Singh S, Loke YK, Enright P, Furberg CD: Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ 2012, 345:e7390. 10.1136/bmj.e7390
26. Jenkins CR, Beasley R: Tiotropium Respimat increases the risk of mortality. Thorax 2013, 68:5-7. 10.1136/thoraxjnl-2012-202482
27. Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, et al.: The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013, 41:1017-1025. 10.1183/09031936.00087312
28. The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2466/15/2/prepub